SQLite Web: event_store.db

Update row 39390 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-14T02:04:49.876253+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:cd0fa1875809f7d4","evidence_event_ids":["evt_c514f73079a2"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1582313/0001193125-26-152834.txt","as_of":"2026-04-14T02:04:49.876253+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1582313/0001193125-26-152834.txt","company":"Xenon Pharmaceuticals Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1582313/0001193125-26-152834.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_faf9a666256f076f","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1582313/0001193125-26-152834.txt","content_type":"text/plain","enriched_at":"2026-04-14T02:08:22.255980+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"8-K","final_url":"https://www.sec.gov/Archives/edgar/data/1582313/0001193125-26-152834.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1582313/0001193125-26-152834.txt","source_event_id":"evt_c514f73079a2","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"95d6f257e4a384d8","kind":"sec_filing","published_at":"20260413","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-07","2026-04-13","2026-04-14"],"entities":[{"asset_class":"equity","name":"Xenon Pharmaceuticals Inc.","relevance":"high","symbol":"XENE","type":"issuer"},{"asset_class":"regulation","name":"Nasdaq Listing Rule 5635(c)(4)","relevance":"medium","symbol":"","type":"regulatory_reference"},{"asset_class":"regulation","name":"Nasdaq Listing Rule 5635(c)(3)","relevance":"medium","symbol":"","type":"regulatory_reference"}],"event_type":"listing","information_gaps":["The provided text does not include the specific changes made by the April 7, 2026 amendment versus the prior version of the plan (no redline/delta content is shown).","The provided text does not list the specific material terms of awards (e.g., grant limits, vesting schedules, exercise prices) beyond definitions and general purpose.","The provided text does not show which 8-K Item(s) the filing relates to, only that Exhibit 10.1 is included in the 8-K.","No prior known state of the plan is included in the signal, so the exact \u201cwhat changed vs prior\u201d cannot be determined from the excerpt alone."],"key_facts":["The 8-K includes Exhibit 10.1 titled \u201cAMENDED and RESTATED 2025 INDUCEMENT EQUITY INCENTIVE PLAN XENON PHARMACEUTICALS INC.\u201d","The plan is \u201cAmended as of April 7, 2026.\u201d","The plan\u2019s purpose is to assist the company in attracting, retaining, and motivating employees by providing inducement awards to individuals entering employment with the company or its subsidiaries.","The plan is intended to meet requirements for inducement grants under Nasdaq Listing Rule 5635(c)(4) (the \u201cInducement Listing Rule\u201d).","Each award is intended to qualify as an employment inducement award under the Inducement Listing Rule or to qualify under an exception relating to acquisition/merger under Nasdaq Listing Rule 5635(c)(3).","The plan defines \u201cAward\u201d to include Options, Share Appreciation Rights, Restricted Share Awards, Restricted Share Unit Awards, and Performance Share Awards.","The plan defines \u201cBlackout Period,\u201d \u201cCause,\u201d and \u201cChange of Control\u201d (with detailed thresholds and exceptions)."],"numeric_claims":[{"label":"Inducement qualification threshold (Change of Control)","value":"more than 50% of outstanding voting securities"},{"label":"Asset threshold for Change of Control","value":"equal to or more than 50% of total gross fair market value of assets"},{"label":"Lookback period for asset acquisition test","value":"12 months"}],"primary_claim":"Xenon Pharmaceuticals Inc. filed an 8-K that contains an \u201cAmended and Restated 2025 Inducement Equity Incentive Plan,\u201d amended as of April 7, 2026.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Xenon Pharmaceuticals Inc. filed a Form 8-K that includes an amended and restated 2025 Inducement Equity Incentive Plan, amended as of April 7, 2026. The plan is designed to provide inducement awards (e.g., options and share awards) intended to qualify under Nasdaq inducement plan requirements.","topics":["SEC filing","8-K","equity incentive plan","inducement awards","Nasdaq listing rules"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Xenon Pharmaceuticals Inc. \u00b7 Filed 20260413","ticker":"XENE","tickers":["XENE"],"title":"XENE filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1582313/0001193125-26-152834.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel